​Vivo Efficacy of Blood stable Thiobenzamides​ ​

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH OLAO

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026Q01123

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
Documents2
The National Institutes of Health (NIH), Office of Logistics and Acquisition Operations (OLAO), has issued a Combined Synopsis/Solicitation under Solicitation No. 75N98026Q01123 for the procurement titled “Vivo Efficacy of Blood stable Thiobenzamides.” This opportunity is classified under NAICS code 325414, which pertains to Biological Product (except Diagnostic) Manufacturing, and is further identified by Product Service Code 6505, indicating a focus on drugs and biologicals. The primary objective of this procurement is to evaluate the in vivo efficacy of blood-stable thiobenzamides. While the detailed scope and specific deliverables are referenced in attached documents (not included in this summary), the project is expected to involve the manufacturing, testing, or analysis of thiobenzamide compounds with demonstrated stability in blood, and the assessment of their biological efficacy in vivo. The intended outcome is to generate data or products that advance the understanding or application of these compounds, likely in a biomedical or therapeutic context. The place of performance for this contract is Bethesda, Maryland, within the United States. The procurement is being managed by the NIH, a federal agency under the Department of Health and Human Services, with the OLAO serving as the contracting office. There are no set-aside restrictions for this solicitation, making it open to all qualified vendors regardless of business size or socioeconomic status. Interested contractors should note that the procurement is currently active, with a response deadline of September 20, 2026, at 13:09. The primary point of contact for this opportunity is Towanda Daniels, who can be reached via email at [email protected] for further information or clarification. Given the nature of the requirement and the classification codes, this opportunity is best suited for organizations with expertise in the manufacturing and evaluation of biological products, particularly those with capabilities in non-diagnostic drug development and in vivo efficacy studies. Contractors should review the attached documents referenced in the solicitation for comprehensive technical requirements, evaluation criteria, and submission instructions. For additional details and to access the full solicitation and attachments, interested parties are encouraged to visit the official notice on SAM.gov at the following URL: https://sam.gov/opp/e1ab2f523edc4f3eb47be6a075978711/view. This procurement represents a significant opportunity for qualified vendors to contribute to NIH’s ongoing research and development efforts in the field of biological therapeutics.